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Respiratory syncytial virus (RSV) is a major viral pathogen of infants that also reinfects adults. During RSV
infection, inflammatory host cell recruitment to the lung plays a central role in determining disease outcome.
Chemokines mediate cell recruitment to sites of inflammation and are influenced by, and influence, the
production of cytokines. We therefore compared chemokine production in a mouse model of immunopatho-
genic RSV infection in which either Th1 or Th2 immunopathology is induced by prior sensitization to
individual RSV proteins. Chemokine expression profiles were profoundly affected by the nature of the pulmo-
nary immunopathology: “Th2” immunopathology in BALB/c mice was associated with increased and prolonged
expression of CCL2 (MCP-1), CXCL10 (IP-10), and CCL11 (eotaxin) starting within 24 h of challenge.
C57BL/6 mice with “Th2” pathology (enabled by a deficiency of CD8 cells) also showed increased CCL2
production. No differences in chemokine receptor expression were detected. Chemokine blockers may therefore
be of use for children with bronchiolitis.
Chemokines are chemoattractive mediators that recruit inflam-
matory cells to sites of infection. In many viral infections, exces-
sive inflammation contributes substantially to disease, which
might be modulated by antichemokine therapy. The role of viral
immunopathology is especially evident in infants and young chil-
dren with bronchiolitis caused by respiratory syncytial virus
(RSV), in which an excessive inflammatory cell recruitment re-
sults in occlusion of the small airways and alveoli (26).
Chemokines selectively control the recruitment of T-cell sub-
sets. For example, Th2 cells express CCR3 and CCR4, while Th1
cells express CXCR3 (29). Different T-cell subsets also make
different chemokines; for example, CCL5 (RANTES) is prefer-
entially expressed by Th1 cells (32). Conversely, CCL2 (MCP-1)
secretion is stimulated by interleukin-4 (IL-4) (22) and directly
mediates T-cell differentiation into the Th2 cytokine-secreting
phenotype (9). A role for chemokines in allergic pulmonary in-
flammation has been demonstrated in mice primed to single an-
tigens, such as ovalbumin (OVA). In particular, CCL2, CCL3
(MIP-1), CCL5, and CCL13 (MCP-4) are important mediators
of inflammatory cell recruitment to the lung, and CCL11
(eotaxin) is the principal chemoattractant for eosinophils in this
model (20).
Chemokines therefore may determine both the extent of
pulmonary inflammation and the nature of the cellular infil-
trate in RSV infection. The BALB/c mouse model allows us to
prime for alternative immunopathological outcomes of RSV
infection, which can be biased toward a Th1 or Th2 phenotype
through prior vaccination with single proteins of RSV (1).
Importantly, in this model, the Th1 or Th2 immunopathology
is induced with the same challenge virus and is dependent on
the prior sensitization. In naı¨ve mice, RSV infection recruits
NK cells into the airways during the first 2 to 3 days, and
thereafter CD4 and CD8 T cells are recruited, peaking at 7
to 10 days after infection; significant proportions of these T
cells secrete gamma interferon (IFN-) (16). CD8 T cells are
the most prominent cell subset during resolution of infection.
Mice preprimed to the fusion (F) protein of RSV develop an
enhanced Th1 response upon subsequent challenge with virus.
IFN--secreting CD4 and CD8 T cells are recruited to the
lung in equal proportions. Conversely, mice primed to the
attachment glycoprotein (G) develop a Th2 cytokine response
after challenge. Th2 T cells and eosinophils are recruited, and
NK and CD8 T-cell responses are reduced (14).
This simple switch between different cytokine responses to
the same viral infection provides a robust model for examining
the control of chemokine secretion. Therefore, we set out to
examine the association of certain chemokines and their re-
ceptors with these divergent immunopathological responses.
We show that mice primed with G protein (Th2) have en-
hanced levels of CCL2, CCL3, CCL11, and CXL10, whereas
mice primed with the F protein (Th1) have enhanced levels of
CCL3 only. In a CD8-deficient C57BL/6 (Th2) model, we show
enhanced levels of CCL2.
MATERIALS AND METHODS
Mice and virus stocks. Female BALB/c and C57BL/6 wild-type or CD8
chain-deficient C57BL/6 mice (5) (Harlan Olac Ltd., Wigginton, United King-
dom) were maintained under specific-pathogen-free conditions according to
institutional and United Kingdom Home Office guidelines and used when 6 to 10
weeks old. RSV (A2 strain) and a recombinant vaccinia virus expressing either
the RSV fusion protein (rVV-F), the RSV attachment glycoprotein (rVV-G), or
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a control construct (rVV-gal) were grown in HEp-2 cells and assayed for
infectivity as described previously (3). UV inactivation of RSV was performed in
a UV Stratalinker (Stratagene) for 10 min. At least four mice were given iden-
tical treatments in each study and compared to identical birth cohort controls.
Data shown are representative of repeated studies.
Mouse infection protocol. Mice were scarified on the rump with 3  106 PFU
of recombinant vaccinia virus. Two to 3 weeks later, mice were challenged
intranasally with 2  106 PFU of RSV. Mice were sacrificed by pentobarbitone
injection and exsanguinated via the femoral vessels. Bronchoalveolar lavage
(BAL) fluid was obtained by inflation of the lungs via the trachea six times with
1.5 ml of 12 mM lidocaine in Eagle’s minimum essential medium (16). BAL
eosinophilia was assessed after staining of cytospin preparations with hematox-
ylin and eosin (H&E), and the BAL cell-free supernatant was retained for
enzyme-linked immunosorbent assays (ELISAs). Lung tissue was snap-frozen for
RNA extraction.
RPA. Total lung RNA was extracted using RNA-Stat-60 (Tel-Test Inc.,
Friendswood, TX). Chemokine or chemokine receptor mRNA expression was
determined using probe kits mCK5 and mCR5, respectively (PharMingen, San
Diego, CA). Probes were transcribed using T7 RNA polymerase in the presence
of -32P-labeled UTP (Amersham Pharmacia Biotech, Uppsala, Sweden).
RNase protection assays (RPAs) were carried out using the RPA III kit (Ambion
Inc., Austin. TX), results were analyzed by polyacrylamide gel electrophoresis,
and band intensity was assessed electronically (Storm PhosphorImager using
ImageQuant, version 4.2a, software; Molecular Dynamics Instruments, Sunny-
vale, CA). Results were normalized to values for two housekeeping genes (L32
and GAPDH). It is noteworthy that the BALB/c genome contains a deletion in
the 3 untranslated region of the CXCL10 gene in a region to which the radio-
labeled probe binds. Consequently, the protected probe is 162 residues long
instead of 181 residues, as in other strains (11). Previous studies of this infection
model using this technique did not take account of this error in the manufac-
turer’s reagent, effectively swapping the protected bands for CXCL10 and CCL2
(10, 34). The mRNA results for these two chemokines have thus been exchanged
in these studies.
Chemokine ELISAs. Concentrations of chemokines in BAL fluid were as-
sessed by ELISAs using the following antibody pairs: for the CCL2 ELISA, an
anti-mouse CCL2 monoclonal antibody (MAb) and a biotinylated anti-CCL2
MAb (2H5; PharMingen); for the CCL3 ELISA, anti-mouse CCL3 and perox-
idase-conjugated anti-CCL3 (R&D Systems); for the CCL5 ELISA, anti-mouse
CCL5 and biotinylated anti-mouse CCL5 polyclonal antibodies (R&D Systems);
for the CCL11 ELISA, an anti-mouse CCL11 MAb and biotinylated anti-CCL11
polyclonal immunoglobulin G (R&D Systems); for the CCL24 ELISA, purified
anti-mouse CCL24 polyclonal immunoglobulin G (R&D Systems) and a perox-
idase-conjugated anti-goat F(ab)2 fragment (Jackson Laboratories).
Statistical analysis. Values were tested for statistical significance by the Mann-
Whitney test or analysis of variance using Minitab (version 12.22; Minitab Inc.),
making allowance for multiple comparisons and correcting significances. P values of
0.05 were considered to be significant, as indicated on the figures and in the text.
RESULTS
Lung chemokine expression in primary RSV infection. The
mRNA expression levels of a number of chemokines were
analyzed in total-lung RNA from BALB/c mice after primary
RSV infection. Figure 1 shows the induction of chemokine
mRNA in RSV-infected mice 24 and 48 h and 7 days after
intranasal inoculation, corresponding to the time of initial cell
recruitment (24 to 48 h) and the time of the peak number of
total lung cells (7 days). Values are shown as n-fold increases
over levels after inoculation with a lysate of HEp-2 cells, the
cell line in which RSV is grown.
In uninfected lungs (Fig. 1, inset), very low levels of several
chemokine mRNA species were detectable; CCL5 was clearly
expressed at the highest levels prior to infection. Intranasal
inoculation with HEp-2 cell lysates upregulated none of the
chemokines examined. After RSV infection, mRNA levels
of all chemokines examined were significantly upregulated.
CXCL10 mRNA levels were most noticeably increased (100-
fold increase; P  0.05 versus HEp-2), but levels were reduced
after 48 to 72 h. They remained above background after 7 days.
A similar pattern was seen in expression of CCL2, CCL3 (MIP-
1), CCL4 (MIP-1), and CXCL2 (MIP-2). Seven days after
infection, CCL5 was the most common mRNA species of those
examined, relative to the housekeeping genes, although not
when expressed as n-fold increase over controls, because of the
high constitutive expression of mRNA for this chemokine.
Taking into account the manufacturer’s error in the probe set
used (see Materials and Methods), our results agree with those
of other studies of primary infection (10, 34).
Chemokine expression in Th1 or Th2 cytokine-biased RSV
infection. Figure 2A shows CCL2 mRNA levels in RSV-chal-
lenged mice previously primed with rVV expressing different
RSV proteins. mRNA levels in whole lungs 24 h after RSV
infection, the time of peak expression in all cases, are shown.
CCL2 was undetectable in uninfected lungs and after instilla-
tion of a control HEp-2 lysate, in contrast to its rapid upregu-
lation after infection with live RSV. While CCL2 mRNA pro-
duction was marginally increased in rVV-F-primed mice (Th1
FIG. 1. Chemokine expression following RSV infection. Groups of four birth-cohorted BALB/c mice were challenged with 2  106 PFU RSV,
and 24 h, 48 h, and 7 days later, levels of chemokine mRNA in whole lungs were assessed by an RNase protection assay. (Inset) Baseline expression
in uninfected mice (0 h) and in mice that had been challenged with Hep-2 cell lysates (the cells in which RSV stocks were grown). Data are shown
as n-fold increase over control data 	 standard error. Data are representative of three similar studies.
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secondary response), there was significantly higher production
after rVV-G priming (Th2 secondary response; 2.5-fold in-
crease; P  0.02 versus rVV-F).
We have previously shown that not all mouse strains develop
Th2-driven pulmonary eosinophilia after RSV challenge (15).
This, therefore, provides a model with which to test whether it
is the priming to the G protein per se or the Th2 response to
it that causes increased CCL2 expression. CCL2 mRNA ex-
pression in C57BL/6 mice, which develop a strong Th1 re-
sponse following rVV-G priming, was not significantly differ-
ent from that in rVV-F-primed BALB/c mice (P  0.05),
suggesting that the cytokines produced in Th2 priming are
specifically associated with increased CCL2 mRNA levels.
Examination of CCL2 protein levels in BAL fluid confirmed
the mRNA results (Fig. 2B). CCL2 protein was also produced
over the first 24 h of infection; in the Th2 cytokine-associated
secondary response, significantly higher concentrations were
present 48 and 72 h after infection compared to rVV-F-primed
mice (P  0.02 and P  0.008, respectively). CCL2 production
in rVV-G-primed C57BL/6 mice, which develop a Th1 re-
sponse after RSV challenge, was dramatically different from
that in similarly treated BALB/c mice.
CCL3 mRNA expression was also induced by RSV infection,
and its expression was greatly enhanced in both rVV-F- and
rVV-G-primed mice (Fig. 3A). In primary infection, signifi-
cantly enhanced levels of CCL3 mRNA were seen only at 7
days after challenge. This was reflected at the protein level in
BAL fluid (Fig. 3B). CCL3 is detectable in BAL fluid early in
primary infection, but these levels also peak on day 7. Protein
concentrations in BAL fluid are higher in both rVV-F- and
rVV-G-primed mice than in primary challenge.
In many instances, CCL11 is a critical chemokine for the
recruitment and retention of eosinophils in inflamed tissue (2).
Low levels of CCL11 mRNA were detectable prior to RSV
infection and were not altered by control inoculations, HEp-2
lysate, or UV-inactivated RSV (Fig. 4A). Over the first 24 h,
there was a significant increase in the detectable mRNA levels
in all groups, with CCL11 mRNA expression induced to a
higher level and more rapidly in rVV-G-primed mice. This was
short-lived, and by 48 h there was no significant difference
between groups. At 7 days postinfection, the CCL11 level in
rVV-G-primed mice had increased significantly compared to
that in rVV-F-primed mice. The level of CCL11 protein de-
FIG. 2. CCL2 expression reflects the immunopathological response
to RSV infection. (A) Levels of CCL2 mRNA were assessed by RNase
protection assays in whole lungs of BALB/c or C57BL/6 mice 24 h
following RSV infection. Each mouse was tested individually (n 
 4
per group). Some mice had been primed 2 to 3 weeks earlier with
either rVV-F, rVV-G, or the control rVV-gal. Results are expressed
as protected band intensity and are percentages of the intensity of the
housekeeping genes L32 and GAPDH. (B) In similar experiments,
CCL2 protein levels were assessed in cell-free BAL fluids by ELISAs
at different time points following RSV infection. , P  0.05 for
comparison of rVV-G- and rVV-F-primed BALB/c mice.
FIG. 3. CCL3 expression in response to RSV infection. (A) Levels
of CCL3 mRNA in whole lungs of BALB/c mice were assessed by
RNase protection assays. Each mouse was tested individually (n 
 4
per group). Some groups of mice had been primed 2 to 3 weeks earlier
with either rVV-F, rVV-G, or rVV-gal. Results are expressed as
protected band intensity and are percentages of the intensity of the
housekeeping genes L32 and GAPDH. Each data point is the mean for
four animals. Error bars, standard errors. (B) CCL3 protein levels in
cell-free BAL fluids from rVV-G- or rVV-F-primed and RSV-infected
BALB/c mice were assessed by ELISA. The limit of detection is 15
pg/ml (dotted line).
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tectable by ELISA in BAL fluid remained at or around back-
ground levels throughout RSV infection (Fig. 4B). There was
intermittent low-level CCL11 protein detectable in BAL fluid
from rVV-G-primed mice, peaking at 24 h postinfection, sim-
ilarly to mRNA levels. CCL24 (eotaxin-2) protein expression
was not seen in BAL fluid; values were below the assay sensi-
tivity at all time points examined regardless of treatment (data
not shown).
As with CCL2 mRNA expression, CXCL10 mRNA was in-
duced in rVV-F-primed mice to a level similar to that detected
in primary RSV infection. In rVV-G-primed mice, however,
CXCL10 mRNA levels were threefold greater 12 and 24 h
following infection (P  0.015) (Fig. 5). Other chemokines,
including XCL1, CCL4, CXCL12, and CX3CL1, were exam-
ined (data not shown); these chemokines were induced by RSV
infection, but there was no difference between Th1- and Th2-
primed animals.
Role of CD8 lymphocytes in CCL2 production during RSV
infection. We hypothesized that in rVV-G-primed BALB/c
mice, enhanced CCL2 expression correlates with the absence
of IFN--producing CD8 T cells. To test the role of CD8 T
cells in controlling the production of CCL2, we primed either
wild-type or CD8-deficient C57BL/6 mice with rVV-G fol-
lowed by RSV challenge. This model was chosen because
C57BL/6 mice do not normally undergo eosinophilia following
rVV-G priming due to the presence of IFN--producing CD8
T cells. In contrast, CD8 T-cell-deficient rVV-G-primed
C57BL/6 mice recruit similar numbers of cells to the lung as
wild-type animals but undergo a Th2-type response and recruit
eosinophils to BAL fluid, a response similar to that seen in
rVV-G-primed BALB/c mice (15). CCL2 mRNA expression
was increased in CD8-deficient mice, although expression fol-
lowed a kinetics different from that for rVV-G-primed BALB/c
mice (Fig. 6). This finding again associates CCL2 production
with a Th2 response to RSV infection and suggests that CD8
cells play a role in limiting the production of CCL2 during
RSV infection.
Lung chemokine receptor expression. In total lungs of naı¨ve
mice, CCR2 mRNA was the most highly expressed chemokine
receptor, although CCR1 and CCR5 mRNAs were also de-
tectable (Fig. 7A). During the first 24 h after RSV infection,
CCR2 underwent a rapid, transient increase in expression.
Following this, increases in CCR1, -2, and -5 mRNAs began at
48 h and broadly paralleled cell infiltration (Fig. 7A, right axis).
CCR2 was the most highly expressed chemokine receptor
throughout. Chemokine receptor expression was not altered by
prior exposure to RSV proteins (Fig. 7B). CC chemokine re-
ceptor expression followed the same pattern in primary RSV
infection as in secondary infection, although slightly delayed,
consistent with delayed cell recruitment (data not shown).
There was no significant mRNA expression at the whole-lung
level of CCR3 or CCR4 (not shown), archetypal in vitro-po-
larized Th2 chemokine receptors, even in mice undergoing
Th2 cytokine-associated secondary inflammation.
DISCUSSION
The selective expression of chemokines or their receptors in
association with Th1 or Th2 cytokine-biased pulmonary in-
flammation may play a central role in determining the outcome
of disease. We have demonstrated that different chemokine
profiles are associated with Th1- or Th2-biased immunopathol-
ogy in response to RSV challenge. CCL2 expression was in-
FIG. 4. CCL11 expression in response to RSV infection. (A) Levels
of CCL11 mRNA in whole lungs of BALB/c mice following RSV
infection were assessed by RNase protection assays. Some mice had
been primed 2 to 3 weeks earlier with rVV-G, rVV-F, or rVV-gal.
Results are expressed as protected band intensity and are percentages
of the intensity of the housekeeping genes L32 and GAPDH. , P 
0.05 for comparison of rVV-G- and rVV-F-primed BALB/c mice.
(B) CCL11 protein levels in cell-free BAL fluids from rVV-primed and
RSV-infected BALB/c mice were assessed by ELISA. The limit of
detection was 37.5 pg/ml (broken line).
FIG. 5. CXCL10 expression in response to RSV infection. Levels
of CXCL10 mRNA in whole lungs of BALB/c mice following RSV
infection were assessed by RNase protection assays. Some groups of
mice (n
 4) had been primed 2 to 3 weeks earlier with rVV-G, rVV-F,
or rVV-gal. Results are expressed as protected band intensity and are
percentages of the intensity of the housekeeping genes L32 and
GAPDH. Each data point is the mean for four animals. Error bars,
standard errors. , P  0.05 for comparison of rVV-G- and rVV-F-
primed BALB/c mice.
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creased and prolonged during Th2 cytokine-mediated immu-
nopathology both in BALB/c mice and in normal or CD8-
deficient C57BL/6 mice. Expression levels of both CCL11 and
CXL10 also increased in Th2-primed BALB/c mice.
A number of other chemokines examined, such as CCL3,
showed no clear association with either inflammatory pheno-
type but were upregulated following priming with either RSV
F (Th1) or RSV G (Th2) protein. Expression of a number of
CC chemokine receptors in the lung was not significantly
altered in cytokine-biased infection. There was a significant
increase in CCR1, CCR2, and CCR5 expression but no de-
tectable CCR3 or CCR4 expression even in Th2 cytokine-
mediated immunopathology. We conclude that although early
chemokine expression is likely to be an innate response to viral
replication, prior priming to individual RSV proteins can alter
cytokine expression even at very early time points after infec-
tion, indicating that specific primed/memory T cells that track
to the lung from distant sites may have an influence on these
early responses.
CCL2 expression was increased during Th2 immunopathol-
ogy in both BALB/c and CD8-deficient C57BL/6 mice, indi-
cating that the overexpression of CCL2 is a feature of the Th2
cytokine response. In other models of Th2-mediated pulmo-
nary inflammation, CCL2 has been shown to be a key mediator
of both cell recruitment and the augmentation of Th2 cytokine
production by T cells (20). CCL2 promotes differentiation of
CD4 T cells to a Th2 phenotype, and mice deficient in CCL2
do not mount Th2 responses and produce low levels of Th2
cytokines (9, 17). CCL2 expressed at the site of inflammation
can drain through the lymphatics to the lymph nodes, where it
directly affects T-cell differentiation (27), and blocking CCL2
during the early stages of allergen challenge reduces T-cell and
eosinophil recruitment in a model of OVA sensitization (7).
CCL2 is induced by expression of IL-4 and inhibited by IFN-
in vitro (13). Therefore, our data support a role for CCL2 in
Th2-mediated immunopathology, even in virally induced eo-
sinophilia. The CCL2 in our model may, but need not, come
directly from T cells, as it is likely that CCL2 expression would
also be induced from macrophages and from epithelium and
surrounding parenchymal cells in response to IL-4 (4, 36, 37).
CCL2 is detectable in nasal lavage fluid during active infection
with RSV (25), although no association with Th2 cytokine-
driven aspects of immunopathology has been previously doc-
umented. It is interesting to hypothesize that CCL2 may play a
role in driving the differentiation of RSV-specific Th2 cells or
that CCL2 can sustain and amplify an existing Th2 cell popu-
lation in the lung. It cannot be ruled out, however, that the
increase in CCL2 expression may be merely a consequence of
increased Th2 cytokine expression and not part of the differ-
entiation process. Experiments to block CCL2 function will be
FIG. 6. (A) CCL2 mRNA expression is increased in rVV-G-
primed CD8-deficient mice. Levels of CCL2 mRNA were assessed by
RNase protection assays in whole lungs of wild-type and CD8/
C57BL/6 mice primed with rVV-G and challenged 2 weeks later with
RSV. Results are expressed as protected band intensity and are per-
centages of the intensity of the housekeeping genes L32 and GAPDH.
Controls are mRNA levels after rVV scarification prior to RSV infec-
tion and 24 h after intranasal inoculation of a Hep-2 cell lysate. , P 
0.05 for comparison of wild-type and CD8/ mice. (B) CCL2 protein
levels in cell-free BAL fluids from wild-type and CD8/ RSV-infected
C57BL/6 mice were assessed by ELISA. The limit of detection is 37.5
pg/ml. In both panels, each data point is the mean for four animals.
Error bars, standard errors.
FIG. 7. Chemokine receptor expression following RSV infection.
Expression of chemokine receptor CCR1, CCR2, and CCR5 mRNAs
in whole lungs of BALB/c mice was assessed by RNase protection
assays. (A) Primary RSV infection. (B) Mice primed with rVV and
challenged 2 weeks later with RSV. Results are expressed as percent-
ages of the intensity of the housekeeping genes L32 and GAPDH.
Each data point is the mean for four animals. Error bars, standard
errors.
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needed to resolve whether CCL2 is a cause or a consequence
of Th2 cell recruitment and differentiation in this model.
CCL3 has been shown to play a role in models of allergic
inflammation: CCL3 is a chemoattractant for eosinophils, ac-
tivated T cells, and monocytes, and neutralization in vivo par-
tially reduces eosinophilia and airway hyperresponsiveness (7,
23). However, in vitro, CCL3 drives the development of Th1
cells (18). In our model, CCL3 production was elevated in mice
primed for either Th1 or Th2 responses compared to primary
infection. Since CCL3 recruits activated T cells, our data sug-
gest that it may be an important factor for sustaining and
amplifying an already primed T-cell response, rather than in-
ducing the differentiation of a particular subset of T-helper
cells.
CCL11 is a chemoattractant for eosinophils, basophils, mast
cells, and Th2 cells which express its receptor, CCR3 (30).
CCL24 has a similar function despite being structurally unre-
lated (37). In our model we saw a rapid early peak of CCL11
expression following the Th2 type rVV-G priming. This
mRNA peak declined at 48 h but rose again at the 7-day time
point. CCL11 protein levels increased following rVV-G prim-
ing at 24 h but not at 7 days. The CCL11 expression profile is
similar to the one we see with CCL5 (RANTES) (F. J. Culley
et al., submitted for publication), where there is a biphasic
response, consisting of an early phase that we believe is caused
by resident cells and a later phase, associated with an influx of
lymphocytes. In the later phase mRNA is transcribed, but
protein is not expressed; however, the protein can be expressed
following RSV restimulation. In the rVV-F-primed mice, we
did not see enhanced CCL11 levels. These data agree with our
previous findings, where treatment with anti-CCL11 reduces
disease in rVV-G-primed mice but not rVV-F-induced pathol-
ogy (24).
The significantly higher expression of CXCL10 in rVV-G-
primed mice following RSV infection was unexpected. Given
that CXCL10 is induced by IFN- and indeed may be part of
the IL-12 signaling pathway (28), it seems counterintuitive that
expression is increased in Th2 cytokine-mediated immunopa-
thology. However, our model contrasts with many other mod-
els of pulmonary inflammation in that we are using a replicat-
ing whole-virus infection to induce immunopathology. Even in
rVV-G-primed mice, there is significant expression of IFN-
(33). Since the preferential recruitment of Th1 cells by
CXCL10 also depends on chemokine receptor and adhesion
molecule expression on target cells, our results demonstrate
that the expression of CXCL10 per se is insufficient to deter-
mine that the inflammation is of a Th1 cytokine phenotype.
There were no significant differences in chemokine receptor
mRNA levels detected in our different models. The increases
in receptor expression observed may be a rapid direct response
to RSV infection, for instance, in macrophages or in epithe-
lium, as seen in the initial peak of CCR2 expression at 12 h
after RSV infection. Expression later in infection is likely to
occur on recruited inflammatory cells, and indeed the increase
in expression of CCR1, CCR2, and CCR5 follows increases in
expression of their ligands CCL2, CCL4, and CCL5. Expres-
sion of CCR3 and CCR4 is seen on Th2-polarized cells in vitro,
CCR3 is expressed on eosinophils, and both are seen in pul-
monary allergic inflammation (6, 21, 31). However, even in
Th2 cytokine-biased RSV infection, we did not detect CCR3
mRNA. It is possible that there is reduced transcription of
CCR3 mRNA in eosinophils and lymphocytes once they are
recruited to the lung. However, this may reflect the very low
expression of the CCR3 ligands CCL11 and CCL24. It is a
possibility, therefore, that the infiltrating cells in RSV-induced
immunopathology do not express significant amounts of che-
mokine receptors that have previously been identified in Th2
cytokine inflammatory responses.
The mechanism by which rVV-G induces Th2 immunopa-
thology in BALB/c mice following subsequent RSV challenge
is not fully understood. Our studies demonstrate that differ-
ences in chemokine secretion patterns occur as early as 12 h
following challenge. Since the mechanism by which rVV-G
scarification induces the overall Th2 cytokine response to RSV
is dependent on T cells (8), it is likely that rapidly responding
T cells migrate from the site of primary vaccination to the lung
and are responsible for this early response. These could be a
population of circulating  T cells that are recruited, having
been primed in the skin, or an  T-cell population that is able
to respond quickly to infection. This mechanism is seen in
Leishmania major infection of BALB/c mice, in which an in-
effective, Th2 cytokine-dominated response to the parasite is
seen (19). In this case, an NK1.1 T-cell population with re-
stricted  T-cell receptor diversity (V8 V4) responds to
parasitic infection within 16 h and rapidly secretes very large
amounts of IL-4, which are necessary and sufficient to sustain
the subsequent Th2 cytokine response to infection (12). It is
quite possible, therefore, that an analogous response could be
established through the priming of G-specific V14 CD4 T
cells, which dominate the T-cell response during rVV-G-
primed Th2 responses in BALB/c mice (35). These cells may
then influence the chemokine environment in the lung to aug-
ment and sustain Th2 immunopathology. It is also possible that
T cells in the lung are remnants of the circulating pool of cells
that are primed following cutaneous vaccination and that they
have no specific lung homing ability. In considering these al-
ternatives, it is relevant that the interval between priming and
challenge makes little difference to the characteristics of the
disease or cellular response if the priming antigen is G or F.
For example, mice that are primed 3 months prior to challenge
behave very similarly to mice that are primed 2 or 3 weeks
earlier (unpublished data).
We have shown that an eosinophilic Th2-mediated response
to RSV was associated with increased and prolonged produc-
tion of CCL2, CCL3, CXCL10, and CCL11 during virus infec-
tion. This pattern of chemokine and receptor expression is not
markedly different from that seen in particulate antigen-driven
models of lung eosinophilia, such as that using OVA (7). Se-
lective blockade of chemokines may elucidate the mechanism
of immunopathology in RSV disease and lead to novel inter-
ventional therapeutics for children with bronchiolitis.
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